

## Product datasheet for TF312217

### IGFBP3 Human shRNA Plasmid Kit (Locus ID 3486)

#### Product data:

<b>Product Type:</b>	shRNA Plasmids
<b>Locus ID:</b>	3486
<b>Synonyms:</b>	BP-53; IBP3
<b>Vector:</b>	pRFP-C-RS (TR30014)
<b>E. coli Selection:</b>	Chloramphenicol (34 ug/ml)
<b>Mammalian Cell Selection:</b>	Puromycin
<b>Format:</b>	Retroviral plasmids
<b>Components:</b>	IGFBP3 - Human, 4 unique 29mer shRNA constructs in retroviral RFP vector (Gene ID = 3486). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRFP-C-RS Vector, TR30015, included for free.
<b>RefSeq:</b>	<a href="#">NM_000598</a> , <a href="#">NM_001013398</a> , <a href="#">NM_000598.1</a> , <a href="#">NM_000598.2</a> , <a href="#">NM_000598.3</a> , <a href="#">NM_000598.4</a> , <a href="#">NM_001013398.1</a> , <a href="#">BC064987</a> , <a href="#">BC064987.1</a> , <a href="#">BC000013</a> , <a href="#">BC018962</a> , <a href="#">NM_000598.5</a>
<b>UniProt ID:</b>	<a href="#">P17936</a>
<b>Summary:</b>	This gene is a member of the insulin-like growth factor binding protein (IGFBP) family and encodes a protein with an IGFBP domain and a thyroglobulin type-I domain. The protein forms a ternary complex with insulin-like growth factor acid-labile subunit (IGFALS) and either insulin-like growth factor (IGF) I or II. In this form, it circulates in the plasma, prolonging the half-life of IGFs and altering their interaction with cell surface receptors. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. [provided by RefSeq, Jul 2008]
<b>shRNA Design:</b>	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



**Performance Guaranteed:** OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).